Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05789758 · ClinicalTrials.gov registry record
A Study to Learn How Nusinersen (Spinraza) Affects Participants With Spinal Muscular Atrophy (SMA) Who Took it Before or During Pregnancy And About The Health of Their Babies
A clinical trial of Muscular Atrophy, Spinal, sponsored by Biogen.
- Recruiting
- Registry status
- 20
- Enrollment target
- 14
- Study locations
NCT05789758 is a study of Muscular Atrophy, Spinal that is actively recruiting participants, run by Biogen. The registered enrollment target is 20 participants, below the 74-participant average among 15 other Muscular Atrophy, Spinal trials with a reported enrollment target (73% lower). The trial reports 14 study locations across 12 states.
The verdict
NCT05789758, a study of Muscular Atrophy, Spinal, is actively recruiting participants, sponsored by Biogen.
- RECRUITING
- Registry status
- 20 participants
- Enrollment target
- 14
- Study locations
Study Summary
In this study, researchers will know more about the effects of nusinersen, also known as Spinraza®, in pregnant participants with spinal muscular atrophy, also known as SMA. This is a drug available for doctors to prescribe for people with SMA. Due to the current treatment options that exist, people with SMA may now reach the age where they can become pregnant. But, there is not enough information known yet about what the effects of nusinersen may be on pregnant people with SMA or on their babies. This is known as an "observational" study, which collects health information about study participants without changing their medical care. The pregnant participants for this study will be found using 3 different groups of SMA study research centers: * ISMAR-US (International SMA Registry in the United States) * UK Adult SMA-REACH (Adult SMA Research and Clinical Hub in the United Kingdom) * SMArtCARE (Austria, Germany, and Switzerland) The main goal of this study is to collect birth and health information from 3 groups of participants and their babies. These groups are: * Those who received nusinersen 14 months before the first day of their last period before getting pregnant * Those who received nusinersen 14.5 months before the day they got pregnant * Those who received nusinersen during any time in their pregnancy The main questions researchers want to learn about in this study are: * Loss of pregnancy overall * Loss of pregnancy before the baby was 20 weeks old * Loss of pregnancy after the baby becomes 20 weeks old * Live births * Loss of the baby after birth * Babies who have problems in their body that develop during pregnancy * Babies who are small for their age while in the participant's uterus * Pregnancy that happens outside of the uterus * How many participants die during pregnancy, while the baby is being born, and up to 12 weeks after delivering the baby * Babies who develop problems in their body after birth Researchers will also compare this informat
Conditions Studied
Interventions
- OTHER No Intervention
Study Locations (14)
Massachusetts
- Boston Children's Hospital - Boston
- Research Site - Cambridge
Greater London
- University College London Hospitals NHS Foundation Trust - London
- St George's University NHS Foundation Trust - London
California
- Stanford Neuroscience Health Center - Palo Alto
New York
- Columbia University Irving Medical Center - New York
Greater Manchester
- The Northern Care Alliance NHS Foundation Trust - Salford
Hampshire
- University Hospital Southampton NHS Foundation Trust - Southampton
Nottinghamshire
- Nottingham University Hospitals Trust - Nottingham
Shropshire
- The Robert Jones and Agnes Hunt Orthopaedic Hospital NHS Foundation Trust - Oswestry
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2023-12-15 |
| Est. Completion | 2033-10-31 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05789758
The ClinicalTrials.gov registry entry for NCT05789758 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 74-participant average among 15 other Muscular Atrophy, Spinal trials with a reported enrollment target (73% lower). The listed sponsor is Biogen, which has 334 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Muscular Atrophy, Spinal appearing as the primary indexed condition, and to 1 intervention - of which No Intervention is the first listed.
NCT05789758 reports 14 study locations spanning 12 distinct geographic areas - top geographies include Massachusetts, Greater London, California.
Frequently Asked Questions
What is clinical trial NCT05789758 about?
NCT05789758 is a clinical study titled "A Study to Learn How Nusinersen (Spinraza) Affects Participants With Spinal Muscular Atrophy (SMA) Who Took it Before or During Pregnancy And About The Health of Their Babies". In this study, researchers will know more about the effects of nusinersen, also known as Spinraza®, in pregnant participants with spinal muscular atrophy, also known as SMA. This is a drug available for doctors to prescribe for people with SMA. Due to the current treatment options that exist, people...
What is the current status of trial NCT05789758?
This trial is currently recruiting. The enrollment target is 20 participants. The study started on 2023-12-15. Estimated completion is 2033-10-31.
What conditions does trial NCT05789758 study?
This clinical trial studies the following conditions: Muscular Atrophy, Spinal.
What interventions are being tested in trial NCT05789758?
The interventions under investigation include: No Intervention (OTHER).
Who is sponsoring clinical trial NCT05789758?
This trial is sponsored by Biogen, which has 334 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05789758 being conducted?
This trial has 14 study locations across California, Massachusetts, New York, Greater London, Greater Manchester. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Muscular Atrophy, Spinal
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Investigate the Pharmacokinetics and Safety of Risdiplam in Infants With Spinal Muscular Atrophy
RECRUITING · Phase 2
-
A Study to Learn About Salanersen's (BIIB115) Effects on Movement and Its Safety When Given Before Symptoms Appear in Babies With Genetically Diagnosed Spinal Muscular Atrophy (SMA)
RECRUITING · Phase 3
-
A Study Evaluating the Effectiveness and Safety of Risdiplam Administered in Pediatric Patients With Spinal Muscular Atrophy Who Experienced a Plateau or Decline in Function After Gene Therapy
RECRUITING · Phase 4
-
A Study Evaluating the Effectiveness and Safety of Risdiplam Administered as an Early Intervention in Pediatric Participants With Spinal Muscular Atrophy After Gene Therapy
RECRUITING · Phase 4
-
A Study to Find Out How Nusinersen is Processed in the Body When Given Through the ThecaFlex DRx™ System in Adult and Pediatric Participants With Spinal Muscular Atrophy (PIERRE-PK)
RECRUITING · Phase 1
-
A Study of Risdiplam in Infants With Genetically Diagnosed and Presymptomatic Spinal Muscular Atrophy
ACTIVE NOT RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.